ConductScience.org, home

Paper7601015

Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Balfour JA and 2 others. Drugs, 1995. Cited by 16 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. Papers, record 7601015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7601015

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
PubMed
Journal
Drugs
PubMed
Year
1995
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
0.73
iCite
Revised in PubMed
2018-11-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Balfour JAJ A
2Todd PAP A
3Peters DHD H

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bacterial InfectionsMajor topic
FleroxacinMajor topic
Animals
Bacteria
Clinical Trials as Topic
Drug Interactions
Humans
Microbial Sensitivity Tests

Source PubMed

References231

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12,920,479The pharmacokinetics and tissue penetration of the fluoroquinolones.Clin Invest Med1989https://conductscience.org/library/papers/2920479PubMed
28,452,165Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study.Am J Med1993https://conductscience.org/library/papers/8452165PubMed
33,264,554Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa.J Antimicrob Chemother1988https://conductscience.org/library/papers/3264554PubMed
43,119,553Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila.J Antimicrob Chemother1987https://conductscience.org/library/papers/3119553PubMed
51,909,831[Bacteriological and clinical studies on fleroxacin in male gonococcal urethritis].Hinyokika Kiyo1991https://conductscience.org/library/papers/1909831PubMed
610,146,890Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.Pharmacoeconomics1993https://conductscience.org/library/papers/10146890PubMed
77,689,444Quinolones in sexually transmitted diseases.Drugs1993https://conductscience.org/library/papers/7689444PubMed
82,569,597Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men.Lancet1989https://conductscience.org/library/papers/2569597PubMed
98,385,956The withdrawal of temafloxacin. Are there implications for other quinolones?Drug Saf1993https://conductscience.org/library/papers/8385956PubMed
102,849,604In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.J Antimicrob Chemother1988https://conductscience.org/library/papers/2849604PubMed
112,116,256Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.Clin Pharmacokinet1990https://conductscience.org/library/papers/2116256PubMed
122,129,330High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic.J Pharm Biomed Anal1990https://conductscience.org/library/papers/2129330PubMed
132,511,802Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2511802PubMed
141,693,968Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.J Med Microbiol1990https://conductscience.org/library/papers/1693968PubMed
158,463,172Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.J Antimicrob Chemother1993https://conductscience.org/library/papers/8463172PubMed
167,927,833Bacterial resistance to fluoroquinolones: lessons to be learned.Infection1994https://conductscience.org/library/papers/7927833PubMed
173,144,539Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.J Antimicrob Chemother1988https://conductscience.org/library/papers/3144539PubMed
183,144,534Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.J Antimicrob Chemother1988https://conductscience.org/library/papers/3144534PubMed
191,482,143Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1482143PubMed
202,114,419Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.J Chromatogr1990https://conductscience.org/library/papers/2114419PubMed

See all 231 references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
35,631,484Metal(II) Complexes of the Fluoroquinolone Fleroxacin: Synthesis, Characterization and Biological Profile.Pharmaceutics2022https://conductscience.org/library/papers/35631484PubMed
34,452,252Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.Pharmaceutics2021https://conductscience.org/library/papers/34452252PubMed
12,908,854Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.Clin Pharmacokinet2003https://conductscience.org/library/papers/12908854PubMed
9,757,930In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.Intensive Care Med1998https://conductscience.org/library/papers/9757930PubMed
9,433,651Effect of age and gender on the pharmacokinetics of grepafloxacin.Clin Pharmacokinet1997https://conductscience.org/library/papers/9433651PubMed
8,799,689Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.Drugs1996https://conductscience.org/library/papers/8799689PubMed
8,741,236Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.Drugs1996https://conductscience.org/library/papers/8741236PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7601015

GET https://conductscience.org/api/papers/v1/7601015/references?page=2